throbber
Howard A. Burris, III, MD
`Curriculum Vitae
`3322 West End Avenue, Suite 900, Nashville, Tennessee 37203 Ph: (615) 329-7274 Fax: (615) 340-1576 Email: howard.burris@scresearch.net
`
`
`
`
`Education
`B.S. Degree:
`
`
`Medical/Graduate:
`
`Intern:
`
`Residency:
`
`Fellowship:
`
`1977-
`1981
`
`1981-
`1985
`
`B.S. of Science
`
`
`Doctor of
`Medicine
`
`1985-
`1986
`
`Categorical
`Medicine
`
`United States
`Military Academy
`
`University of South
`Alabama, College of
`Medicine
`
`Brooke Army
`Medical Center
`
`1986–
`1988
`
`Residency in
`Internal Medicine
`
`Brooke Army
`Medical Center
`
`1988-
`1991
`
`Fellowship in
`Hematology/
`Medical Oncology
`
`Brooke Army
`Medical Center
`
`West Point,
`New York
`
`Mobile,
`Alabama
`
`Fort Sam
`Houston, Texas
`
`Fort Sam
`Houston, Texas
`
`Fort Sam
`Houston, Texas
`
`Diplomate of the National
`Board of Medical Examiners
`
`Medical Doctor
`
`
`Diplomate of the American
`Board of Internal Medicine
`
`Medical Doctor
`
`
`Diplomate of the American
`Board of Medical Oncology
`
`Medical Doctor
`
`
`
`Diplomate of the American
`Board of Medical Oncology
`
`Diplomate of the American
`Board of Medical Oncology
`
`Licensure/Certifications
`Board Certification 1986
`
`
`
`
`Pennsylvania State Licensure
`
`
`
`
`Texas State Licensure
`
`
`Recertification Completed in
`2001
`
`Tennessee State Licensure
`
`
`
`Recertification Completed in
`2011
`
`Certifcation valid through
`12/31/2021
`
`
`Division of Health
`Related Boards
`
`Board Certification
`
`
`Division of Health
`Related Boards
`
`Board Certification
`
`
`1987
`
`
`1988
`
`
`1991
`
`
`1991
`
`
`1997
`
`
`
`2001
`
`
`
`2011
`
`
`Division of Health
`Related Boards
`
`Board Certification
`
`
`
`Board Certification
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 1 of 80
`
`

`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Fort Sam
`Houston, Texas
`
`
`
`San Antonio,
`Texas
`
`
`
`San Antonio,
`Texas
`
`
`
`San Antonio,
`Texas
`
`
`
`San Antonio,
`Texas
`
`
`
`Fort Sam
`Houston, Texas
`
`San Antonio,
`Texas
`
`San Antonio,
`Texas
`
`
`
`
`Sarah Cannon
`
`
`
`Sarah Cannon Research Institute
`
`
`
`Sarah Cannon Research Institute
`
`Sarah Cannon Research Institute
`
`
`
`
`
`Practice Area
`Oncology
`
`Professional Employment
`President, Clinical
`2012 -
`Operations
`Present
`
`
`Executive Director,
`2011-
`Drug Development
`Present
`
`
`Chief Medical
`2006-
`Officer
`Present
`
`Director of Drug
`Development
`
`1997-
`2010
`
`Associate
`
`Director of Drug
`Development
`Program
`
`1997-
`Present
`
`Tennessee Oncology, PLLC
`
`1990-
`1997
`
`Brooke Army Medical Center (Oncology
`Service)
`
`Associate Professor 1996-
`1997
`
`Director of Clinical
`Research
`
`1993-
`1995
`
`Associate Director
`of Clinical Research
`
`1992-
`1993
`
`Assistant Professor
`
`Staff (Hematology/
`Oncology Service)
`
`Staff (Hematology/
`Oncology Service)
`
`Clinical Instructor
`
`1991-
`1996
`
`1991-
`1997
`
`1991-
`1997
`
`1990-
`1991
`
`The University of Texas Health Science
`Center (Department of
`Medicine/Oncology)
`
`Cancer Therapy and Research Center of
`South Texas (Institute for Drug
`Development)
`
`Cancer Therapy and Research Center of
`South Texas (Institute for Drug
`Development)
`
`The University of Texas Health Science
`Center at San Antonio (Department of
`Medicine/Oncology)
`
`Brooke Army Medical Center
`(Department of Medicine)
`
`Cancer Therapy and Research Center of
`South Texas
`
`The University of Texas Health Science
`Center at San Antonio (Department of
`Medicine/Oncology)
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 2 of 80
`
`

`
`
`
`
`
`
`
`Professional Associations
`American Society of Clinical Oncology
`American College of Physicians
`American Society of Hematology
`Southwest Oncology Group
`Southern Association for Oncology
`(Affiliation of Southern Medical
`Association)
`International Association for the Study of
`Lung Cancer (IASLC)
`
`Associate Member
`Fellow
`Associate Member
`Associate Member
`Associate Member
`
`Associate Member
`
`1980
`1981
`1986
`Academic Year 1987-
`1988
`
`US Military Academy
`US Military Academy
`Brooke Army Medical Center
`
`
`Professional Honors
`Phi Kappa Phi
`Distinguished Military Graduate
`Letter of Commendation
`John Carpenter Outstanding Research
`Award
`
`Commander’s Award for Outstanding
`Research (Honorable Mention)
`
`Promotion to Major
`Meritorious Service Medal
`The Surgeon General’s Physician
`Recognition Award
`
`Meritorious Service Medal (w/oak leaf
`cluster)
`
`Fellow
`Army Commendation Medal
`
`
`
`US Army
`Brooke Army Medical Center
`
`
`
`Brooke Army Medical Center
`
`
`American College of Physicians
`Operation Joint Endeavor
`(Bosnia)
`
`US Army
`Southern Association for
`Oncology
`OncLive
`
`1991
`
`1991
`1992
`1994
`
`1994
`
`
`
`Elected January 1995
`1997
`
`Promotion to Lieutenant Colonel
`President
`
`1997
`2001-2002
`
`Giant of Cancer Care Award
`
`2014
`
`Professional Memberships
`CTRC Clinical Practice Committee (Vice Chairman)
`Institute for Drug Development Project Committee
`
`1991-1995
`1991-1996
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 3 of 80
`
`

`
`
`
`
`
`
`
`Drug Development Program Committee (San Antonio
`Cancer Institute)
`Clinical Investigations Committee (San Antonio Cancer
`Institute)
`Board Member (Hospice S.A., Inc.)
`Brooke Army Medical Center Institutional Review Board
`Brooke Army Medical Center Clinical Investigations
`Committee
`Board Member (Southern Association for Oncology)
`Minnie Pearl Research Foundation Board
`Board Member (Gilda’s Club)
`ASCO Program Training Committee
`Centennial Medical Center Institutional Review Board
`ASCO Clinical Practice Committee
`ASCO Education Committee
`ASCO Sponsorship Sub-Committee
`ASCO Scientific Program Committee
`ASCO Ethics Committee
`ASCO Board of Directors Committee
`ASCO Nominating Committee
`ASCO Cancer Research Committee
`
`1992-1996
`
`1992-1996
`
`1993-1996
`1995-1997
`1995-1997
`
`1997-Present
`1998-Present
`1998-Present
`1999-2002
`2000-Present
`2001-Present
`2002-Present
`2003-2005
`2004-Present
`2004-Present
`2006-2009
`2010-2013
`2013 - Present
`
`Publications
`
`Manuscripts:
`
`1. Wall, J., Burris, H., Von Hoff, D.D., Rodriguez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T., Brown, T.,
`Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Friedman, C., Smith, B., Mann, W., Kuhn, J.: A
`phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864)
`given as an intravenous bolus every twenty-one days. Anticancer Drugs 3:337-345, 1992.
`
`2. Burris, H.A., Rothenberg, M., Kuhn, J.G., Von Hoff, D.D.: Clinical trials with the topoisomerase I inhibitors.
`Seminars in Oncology 19:663-669,1992.
`
`3. Burris, H.A., III, Hanauske, A.R., Johnson, R., Marshall, M.H., Kuhn, J.G., Hilsenbeck, S.G., Von Hoff, D.D.:
`Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in
`vitro. J Nat’l Cancer Inst 84:1816-1820, 1992.
`
`4. Von Hoff, D.D., McGill, J., Davidson, K., Forseth, B., Ebrahim, A., Burris, H.: Preclinical leads for innovative
`uses for etoposide. Seminars in Oncology 19(6) (suppl) 13:10-13, 1992.
`
`
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 4 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5. Shaffer, D.W., Burris, H.A., O'Rourke, T.J.: Testicular relapse in adult acute myelogenous leukemia. Cancer
`70:1541-1544, 1992.
`
`6. Rinaldi, D.A., Lippman, S.M., Burris, H.A., III, Chou, C., Von Hoff, D.D., Hong, W. K.: Phase II study of 13-
`cis-retinoic acid and alpha-2a interferon in patients with advanced squamous cell lung cancer. Anti-
`Cancer Drugs 4:33-36, 1993.
`
`7. Eckardt, J.R., Burris, H.A., Rothenberg, M., Von Hoff, D.D., Kuhn, J.: Topoisomerase-I inhibitors:
`Promising novel compounds. Contemp Oncol 3:47-60, 1993.
`
`8. Burris, H., Irvin, R., Kuhn, J., Kalter, S., Smith, L., Shaffer, D., Fields, S., Weiss, G., Eckardt, J., Rodriguez, G.,
`Vreeland, F., Bayssas, M., LeBail, N., Von Hoff, D.: A phase I clinical trial of taxotere given as either a 2-
`hour or as a 6-hour intravenous infusion. J Clin Oncol 11(5):950-958, 1993.
`
`9. Shaffer, D.W., Smith, L. S., Burris, H.A., Clark, G.M., Eckardt, J.R., Fields, S.M., Weiss, G.R., Rinaldi, D.A.,
`Bowen, K.J., Kuhn, J.G., Von Hoff, D.D.: A randomized phase I trial of chronic oral etoposide with or
`without granulocyte-macrophage colony stimulating factor in patients with advanced malignancies.
`Cancer Res 53:5929-5933, 1993.
`
`10. Rothenberg, M.L., Kuhn, J.G., Burris, H.A., III, Nelson, J., Eckardt, J.R., Tristan-Morales, M., Hilsenbeck,
`S.G., Weiss, G.R., Smith, L.S., Rodriguez, G.I., Rock, M.K., Terada, K., Von Hoff, D.D.: A phase I and
`pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11):2194-2204, 1993.
`
`11. Vukelja, S.J., Baker, W.J., Burris, H.A., III, Keeling, J.H., Von Hoff, D.D.: Pyridoxine hydrochloride therapy
`for palmar-plantar erythrodysesthesia associated with taxotere. (Letter) J Nat’l Cancer Inst 85(17):1432-
`1433, 1993.
`
`12. Burris, H.A., III: The future of cytokines. Oncology (12) (suppl) 7:55-58, 1993.
`
`13. Burris, H.A., III: Preclinical pharmacology and phase I clinical trials of paclitaxel. Proceedings from
`Pharmaceutical Issues of Taxol, University of Arizona, pp. 8-13, 1993.
`
`14. Eckardt, J.R., Burris, H.A., III, Kuhn, J.G., Bissery, M.C., Klink-Alakl, M., Clark, G.M., Von Hoff, D.D.: Activity
`of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-
`forming units in vitro. J Nat’l Cancer Inst, 86 (1): 30-33, 1994.
`
`15. Burris HA 3rd: Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
`Ann Pharmacother 28(5 Suppl): S7 – 10. Review, 1994.
`
`16. Bowen, K., Fields, S., Burris, H.: Topoisomerase I inhibitors: a new class of anticancer agents. Adv in
`Oncology (10) 2:16-21, 1994.
`
`17. Muggia F.M., Burris H.A. III: Clinical development of topoisomerase-interactive drugs. Adv in
`Pharmacology 29B:1-31, 1994.
`
`
`18. Brown, T.D., O'Rourke, T.J., Kuhn, J.G., Craig, J.B., Havlin, K., Burris, H.A. III, Cagnola, J., Hamilton, J.M.,
`Grindey, G.B., Satterlee, W.G., Von Hoff, D.D.: Phase I trial of sulofenur (LY186641) given orally on a daily
`x 21 schedule. Anti-Cancer Drugs (5):151-159, 1994.
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 5 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`19. Shimada, Y., Rothenberg, M., Hilsenbeck, S.G., Burris, H.A., III, Degen, D., Von Hoff, D.D.: Activity of CPT-
`11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
`Anti-Cancer Drugs (5): 202-206, 1994.
`
`20. O'Rourke, T.J., Brown, T.D., Havlin, K., Kuhn, J.G., Craig, J.B., Burris, H.A., Satterlee, W.G., Tarassoff, P.G.,
`Von Hoff, D.D.: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
`(Letter) Eur J Cancer 30A(3):417-418, 1994.
`
`21. Zimmerman, G.C., Keeling, J.H., Lowry, M., Burris, H.A., Von Hoff, D.D.: Prevention of docetaxel-induced
`erythrodypesthesia with local hypothermia. (Letter) J Nat’l Cancer Inst 86(7):557-558, 1994.
`
`22. Eckardt, J.R., Campbell, E., Burris, H.A., Weiss, G.R., Rodriguez, G.I., Fields, S.M., Thurman, A.M., Peacock,
`N.W., Cobb, P., Rothenberg, M.L., Ross, M.E., Von Hoff, D.D.: A phase II trial of DaunoXome7, liposome
`encapsulated daunorubicin in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol
`17(6):498-501, 1994.
`
`23. Von Hoff, D.D., Burris, H.A., III, Eckardt, J., Fields, S.M., Chen, S.-F., Kuhn, J.G.: Preclinical and phase I trials
`of topoisomerase I inhibitors. Cancer Chemother and Pharmacol 34(Suppl):41-45, 1994.
`
`24. Burris, H.A. III, Eckardt, J.R., Awada, A., Fields, S., Rodriguez, G.I., Smith, S., Weiss, G.R., Rinaldi, D.A., Clark
`G., Casenave, L., Von Hoff, D.D., Kuhn, J.G.: Phase I and pharmacokinetic studies of topotecan
`administered as a 72- or 120-Hour continuous infusion. Anti-Cancer Drugs (5):394-402, 1994.
`
`25. Zimmerman, G.C., Keeling, J.H., Burris, H.A., Cook, G., Irwin, R., Kuhn, J., McCollough, M.L., Von Hoff, D.D.:
`Acute cutaneous reactions to taxotere (RP 56976), a new chemotherapeutic agent. Ann Int Med (In
`Press), 1994.
`
`26. Cobb, P.W., Clark, G.M., Kuhn, J.G., Kirshenbaum, M.R., Burris, H.A. III, Von Hoff, D.D.Activity of DMP840,
`a new bis-naphthalimide, on primary human tumor colony-forming units. J Nat’l Cancer Inst 86:1462-
`1465, 1994.
`
`27. Burris, H.A., III and Fields, S.: Summary of data from in vitro and phase I navelbine studies. Seminars in
`Oncology 21:14-20, 1994.
`
`28. Fields, S.M., Burris, H.A., III: Irinotecan: a new topoisomerase I inhibitor with promising antitumor
`activity. Highlights in Antineoplastic Agents 12:68-72, 1994.
`
`29. O'Rourke, T.J., Weiss, G.R., New, P., Burris, H.A., Rodriguez, G., Eckardt, J., Hardy, J., Kuhn, J.G., Fields,
`S.M., Clark, G.M., Von Hoff, D.D.: Phase I clinical trial of ormaplatin (Tetraplatin, NSC363812) given on a
`daily times five every 28 day schedule. Anti-Cancer Drugs 5(5):520-526, 1994.
`
`
`30. Weiss, G.R., Kuhn, J.R., Rizzo, J., Smith, L.S., Rodriguez, G.I., Eckardt, J.R., Burris, H.A. III, Fields, S.,
`VanDenBerg, C., Von Hoff, D.D.: A phase I and pharmacokinetic study of 2-chlorodeoxyadenosine in
`patients with solid tumors. Cancer Chemother Pharmacol 35:397-402, 1995.
`
`31. Bedikian, A.Y., Weiss, G.R., Legha, S.S., Burris, H.A., Eckardt, J.R., Jenkins, J., Eton, O., Buzaid, A.C.,
`Smetzer, L., Von Hoff, D.D., Benjamin, R.S.: Phase II trial of docetaxel (taxotere, RP56976) in patients with
`advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 6 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`13(12):2895-2899, 1995.
`
`32. Rinaldi, D.A., Burris, H.A., Dorr, F.A., Woodworth, J.R., Kuhn, J.G., Eckardt, J.R., Rodriguez, G., Corso, S.W.,
`Fields,S.M., Nelson, J., Clark, G., Farie,s D., Lu, P., Von Hoff, D.D.: Initial phase I evaluation of the novel
`thymidylate synthase inhibitor, LY231514, utilizing the modified continual reassessment method for dose
`escalation. J Clin Oncol 13(11):2842-2850, 1995.
`
`33. Ravdin P.M., Burris H.A., Cook G., et al: Phase II trial of docetaxel in advanced anthracycline-
`resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
`
`34. Grunberg, S.M., Burris H., III, Livingston, R.: The price of success. (Letter to the Editor) J Clin Oncol 13:797-
`798, 1995
`
`35. Burris, H.S., Fields S., Peacock, N.: Docetaxel (Taxotere) in combination: a step forward. Semin Oncol
`22(6 Suppl 13):35-40, 1995.
`
`36. Kolesar, J.M., Kuhn, J.G., Burris, H.A.: Detection of a point mutation in NQ01 (DT-diaphorase) in a patient
`with colon cancer. J Nat’l Cancer Inst 87(13:1022-4, 1995.
`
`37. Battafarano D. F., Zimmerman, G.C., Older, S.A., Keeling, J.H., Burris, H.A.: Docetaxel (Taxotere)
`associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 78(1):110-
`5, 1995.
`
`38. Zimmerman, G.C., Keeling, J.H., Burris, H.A., Cook, G., Irvin, R., Kuhn, J., McCollough, M.L., Von Hoff, D.D.:
`Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131(2):202-6,
`1995.
`
`39. Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, von Hoff DD, Vaickus L:
`Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX)
`before and after cytotoxic chemotherapy. Ann N Y Acad Sci 21: 762: 359 – 360, 1995.
`
`40. Rothenberg, M.L., Eckardt, J.R., Kuhn, J.G., Burris, H.A., III, Nelson, J., Hilsenbeck, S.G., Rodriguez, G.I.,
`Thurman, A.M., Smith, L.S., Eckhardt, S.G., Weiss, G.R., Elfring, G.L., Rinaldi, D.A., Schaaf, L.J., Von Hoff,
`D.D.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin
`Oncol 14(4):1128-1135, 1996.
`
`41. Jones S.F, Burris H.A. III: Vinorelbine: A new antineoplastic drug for the treatment of non-small cell lung
`cancer. Annals of Pharmacotherapy 30(5):501-506, 1996.
`
`42. Rothenberg, M.L., Moore, M.J., Cripps, M.C., Andersen, J.S., Portenoy, R.K., Burris, H.A., III, Green, M.R.,
`Tarassoff, P.G., Brown, T.D., Casper, E.S., Storniolo, A.-M., Von Hoff, D.D.: A phase II trial of gemcitabine
`in patients with 5-FU-refractory pancreas cancer. Annals of Oncol 7:347-353, 1996.
`
`43. Eckhardt, S.G., Burris, H.A., Eckardt, J.R., Weiss, G., Rodriquez, G., Rothenberg, M., Rinaldi, D., Barrington,
`R., Kuhn, J.G., Masuo, K., Sudo, K., Atsumi, R., Oguma, T., Higashi, L., Fields, S., Smetzer, Von Hoff, D.D.: A
`phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of
`Oncol 7:491-496, 1996.
`
`44. Burris H.A. III: Optimal use of docetaxel (Taxotere): Maximizing it’s potential. Anti-Cancer Drugs
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 7 of 80
`
`

`
`
`
`
`
`7(Suppl)2:25-28, 1996.
`
`45. Burris H.A. III: Objective outcome measures of quality of life. Oncology 10(11 Suppl):131-135, 1996.
`
`46. Burris, H., Hesketh, P., Cohn, J., Moriconi, W., Ryan, T., Friedman, C., Fitts, D.: Efficacy and Safety of Oral
`Granisetron versus Oral Oprochlorperazine in Preventing Nausea and Emesis in Patients Receiving
`Moderately Emetogenic Chemotherapy. Cancer J Sci Am 2(2):85, 1996.
`
`47. Cunningham, D., Zalcberg, J., Smith, I., Gore, M., Pazdur, R., Burris, H., Meropol, N.J., Kennealey, G.,
`Seymour, L.: ‘Tomudex’ (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour
`activity in a range of solid tumors. ‘Tomudex’ International Study Group. Ann Oncol 7(2):179-82, 1996.
`
`48. Jones, S.F., Burris, H.A.: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Prac 4(1):51-3,
`1996.
`
`49. New, P.Z., Jackson, C.E., Rinaldi, D., Burris, H., Barohn, R.J.: Peripheral neuropathy secondary to
`docetaxel. Neurology 46(1):108-11, 1996.
`
`50. Burris H.A. III, Storniolo A.M.: Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine
`compared to 5-Fluorouracil. European Journal of Cancer 33(Suppl)1:S18-22, 1997.
`
`51. Burris H.A. III, Dieras V.C., Tunca M., Earhart R.H., Eckardt J.R., Rodriguez G.I., Shaffer D.S., Fields
`S.M., Campbell E., Schaaf L., Kasunic D., Von Hoff D.D.: Phase I study with the DNA sequence-specific
`agent adozelesin. Anti-Cancer Drugs 8(6):588-596, 1997.
`
`52. Burris, H.A., III, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps,
`M.C., Portenoy, R.K., Storniolo, A.M., Tarrassoff, P., Nelson, R., Von Hoff, D.D.: Improvements in
`survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas
`cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
`
`53. Creemers, G.J., Gerrits, C.J.H., Eckardt, J.R., Schellens, J.H.M., Burris, H.A., Planting, A.S.Th.,
`Rodriguez, G.I., Loos, W.J., Hudson, I., Broom, C., Verweij, J., Von Hoff, D.D.: Phase I and
`pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with
`solid tumors. J Clin Oncol 15:1087-1093, 1997.
`
`54. Rowinsky E., Smith L., Rodriguez G., White L., Drengler R., Von Hoff D., Peacock N., Aylesworth C.,
`Burris H.A. III, Ravdin P., Bellet R.: Docetaxel in combination with fluorouracil: Study design and
`preliminary results. Oncology 11 (6 Suppl 6):35-35, 1997.
`
`
`55. Raymond E., Burris H.A., Rowinsky E.K., Eckardt J.R., Rodriguez G., Smith L., Weiss G., Von Hoff D.D.:
`Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously
`untreated non-small cell lung carcinoma. Ann of Oncol 8(10):1003-1008, 1997.
`
`56. Benedetti, J.K., Burris, H.A., Balcerzak, S.P., MacDonald, J.S.: Phase II trial of topotecan in advanced
`gastric cancer: a Southwest Oncology Group study. Invest New Drugs 15(3):261-4, 1997.
`
`57. Burris, H.A.: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology
`11(Suppl 8):50-2, 1997
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 8 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`58. Bruno R., Hille D., Riva A., Vivier N., ten Bokkel Huinnink W.W., van Oosterom A.T., Kaye S.B., Verweij
`J., Fossela F.V., Valero V., Rigas J.R., Seidman A.D., Chevallier B., Fumoleau P., Burris H.A., Ravdin P.M.,
`Sheiner L.B.: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in
`patients with cancer. J Clin Oncol 16(No. 1):187-196, 1998.
`
`59. Burris H.A. III: Topotecan: Incorporating it into the treatment of solid tumors. The Oncologist 3:1-3,
`1998.
`
`60. Rothenberg M.L., Sharma A., Weiss G.R., Villalona-Calero M.A., Eckardt J.R., Aylesworth C., Kraynak
`M., Rinaldi D.A., Rodriguez G.I., Burris, H.A., Eckhardt S.G., Stephens C.D., Forral K., Nichol S., Von Hoff
`D.D.: Phase I trial of paclitaxel and gemcitabine in patients with refractory solid tumors. Ann of Oncol
`9(7): 733-738, 1998.
`
`61. Schilsky R.L., Hohneker J., Ratain M.J., Janisch L., Smetzer L., Lucas V.S., Khor S.P., Diasio R., Von Hoff
`D.D., Burris H.A.: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients
`with advanced cancer. J Clin Oncol 16(4):1450-1457, 1998.
`
`62. Hainsworth J.D., Burris H.A., Erland J.B., Thomas M., Greco F.A.: Phase I trial of docetaxel
`administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16(6):2164-
`2168, 1998.
`
`63. Burris, H.: Weekly schedules of docetaxel. Semin Oncol 25(6 Suppl 13):21-3, 1998.
`
`64. Gerrits, C.J., Burris, H., Schellens, J.H., Planting, A.S., van den Burg, M.E., Rodriguez, G.I., van Beurden,
`V., Loos, W.J., Hudson, I., Fields, S., Verweij, J., Von Hoff, D.D.: Five days of oral topotecan (Hycamtin),
`a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 34(7):1030-5,
`1998.
`
`65. Valero, V., Jones, S.E., Von Hoff, D.D., Booser, D.J., Mennel, R.G., Ravdin, P.M., Holmes, F.A., Rahman,
`Z., Schottstaedt, M.W., Erban, J.K., Esparza-Guerra, L., Earhart, R.H., Hortobagyi, G.N., Burris, H.A.: A
`phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol
`16(10):3362-8, 1998.
`
`66. Peacock, N.W., Burris, H.A., Dieras, V., Smith, L., Rodriguez, G.I., Eckardt, J.R., Jones, S.F., Hardy, J.,
`Hohneker, J., Bigley, J., Von Hoff, D.D.: A phase I trial of vinorelbine in combination with mitoxantrone
`in patients with refractory solid tumors. Invest New Drugs 16(1):7-43, 1998.
`
`
`67. Burris, H.A., Raymond, E., Awada, A., Kuhn, J.G., O’Rourke, T.J., Brentzel, J., Lynch, W., King, S.Y.,
`Brown, T.D., Von Hoff, D.D.: Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC
`368390) in combination with cisplatin in patients with advanced malignancies. Invest New Drugs
`16(1):19-27, 1998.
`
`68. Hammond, L.A., Eckardt, J.R., Ganapathi, R., Burris, H.A., Rodriguez, G.A., Eckhardt, S.G., Rothenberg,
`M.L., Weiss, G.R., Kuhn, J.G., Hodges, S., Von Hoff, D.D., Rowinski, E.K.: A phase I and translational
`study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
`Clin Cancer Res 4(6):1459-67, 1998.
`
`69. Gerrits, C.J., Burris, H., Schellens, J.H., Eckardt, J.R., Planting, A.S., van der Burg, M.E., Rodriguez, G.I.,
`Loos, W.J., van Beurden, V., Hudson, I., Fields, S., Von Hoff, D.D., Verweij, J: Oral topotecan given
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 9 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
`Clin Cancer Res 4(5):1153-8, 1998.
`
`70. Villalona-Calero, M.A., Eckardt, J., Burris, H., Kraynak, M., Fields-Jones, S., Bazan, C., Lancaster, J.,
`Hander, T., Goldblum, R., Hammond, L., Bari, A., Drengler, R., Rothenberg, M., Hadovsky, G., Von Hoff,
`D.D.: A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain
`edema. Ann Oncol 9(1):71-7, 1998.
`
`71. Eckhardt, S.G., Baker, S.D., Eckardt, J.R., Burke, T.G., Warner, D.L., Kuhn, J.G., Rodriguez, G., Fields, S.,
`Thurman, A., Smith, L., Rothenberg, M.L., White, L., Wissel, P., Kunka, R., DePee, S., Littlefield, D.,
`Burris, H.A., Von Hoff, D.D., Rowinsky, E.K.: Phase I and pharmacokinetic study of GI147211, a water-
`soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin
`Cancer Res 4(3):595-604, 1998.
`
`72. Burris, H.A., Voge., C.L., Castro, D., Mishra, L., Schwarz, M., Spencer, S., Oakes, D.D., Korey, A.,
`Orenberg, E.K.: Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for
`accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 118(4):496-503, 1998.
`
`73. Burris, H.A.: The evolving role of oral topotecan. Semin Hematol 36(4 Suppl 8):26-32, 1999.
`
`74. Villalona-Calero, M.A., Weiss, G.R., Burris, H.A., Kraynak, M., Rodriguez, G., Drengler, R.L., Eckhardt,
`S.G., Reigner, B., Moczygemba, J., Burger, H.U., Griffin, T., Von Hoff, D.D., Rowinsky, E.K.: Phase I and
`pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in
`patients with advanced solid malignancies. J Clin Oncol 17(6):1915, 1999.
`
`75. Rinaldi, D.A., Kuhn, J.G., Burris, H.A., Dorr, F.A., Rodriguez, G., Eckhardt, S.G., Jones, S., Woodworth,
`J.R., Baker, S., Langley, C., Mascorro, D., Abrahams, T., Von Hoff, D.D: A phase I evaluation of multi-
`targeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual
`reassessment method for dose escalation. Cancer Chemother Pharmacol 44(5):372-80, 1999.
`
`76. Hesketh, P.J., Crowley, J.J., Burris, H.A., Williamson, S.K., Balcerzak, S.P., Peereboom, D., Goodwin,
`J.W., Gross, H.M., Moore, D.F. Jr., Livingston, R.B., Gandara, D.R.: Evaluation of docetaxel in
`previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II
`trial. Cancer J Sci Am 5(4):237-41, 1999.
`
`
`77. Hainsworth, J.D., Burris, H.A., Greco, F.A.: Weekly administration of docetaxel (Taxotere): summary
`of clinical data. Semin Oncol 26(3 Suppl 10):19-24, 1999.
`
`78. Burris, H.A.: Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 26(3 Suppl
`9):1-6, 1999.
`
`79. Hainsworth, J.D., Burris, H.A., Erland, J.B., Morrissey, L.H., Meluch, A.A., Kalman, L.A., Hon, J.K., Scullin,
`D.D. Jr., Smith, S.W., Greco, F.A.: Phase I/II trial of paclitaxel by 1-hour infusion carboplatin, and
`gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer
`85(6):1269-76, 1999.
`
`80. Petit, T., Aylesworth, C., Burris, H., Ravdin, P., Rodriguez, G., Smith, L., Peacock, N., Smetzer, L., Bellet,
`R., Von Hoff, D.D., Rowinsky, E.K.: A phase I study of docetaxel and 5-fluorouracil in patients with
`advanced solid malignancies. Ann Oncol 10(2):223-9, 1999.
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 10 of 80
`
`

`
`
`
`
`
`81. Hainsworth, J.D., Burris, H.A., Morrissey, L.H., Greco, F.A.: Phase I trial of paclitaxel, carboplatin, and
`topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of
`patients with advanced, refractory cancer. Cancer 1;85(5):1179-85, 1999.
`
`82. Diab, S.G., Baker, S.D., Joshi, A., Burris, H.A., Cobb, P.W., Villalona-Calero, M.A., Eckhardt, S.G., Weiss,
`G.R., Rodriguez, G.I., Drengler, R., Kraynak, M., Hammond, L., Finizio, M., Von Hoff, D.D., Rowinsky,
`E.K.: A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced
`solid tumors. Clin Cancer Res 5(2):299-308, 1999.
`
`83. Pazdur, R., Royce, M.E., Rodriguez, G.I., Rinaldi, D.A., Patt, Y.Z., Hoff, P.M., Burris, H.A.: Phase II trial of
`docetaxel for cholangiocarcinoma. Am J Clin Oncol 22(1):78-81, 1999.
`
`84. Gerrits, C.J., Schellens, J.H., Burris, H., Eckardt, J.R., Planting, A.S., van der Burg, M.E., Rodriguez, G.I.,
`Loos, W.J., van Beurden, V., Hudson, I., Von Hoff, D.D., Verweij, J.: A comparison of clinical
`pharmacodynamics of different administration schedules or oral topotecan. Clin Cancer Res 5(1):69-
`75, 1999.
`
`85. Fields-Jones S, Koletsky A, Wilding G, O’Rourke M, O’Rourke T, Eckardt J, Yates B, McGuirt C, Burris HA
`3rd: Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory
`prostate cancer: a phase II trial. Ann Oncol 10(11): 1307 – 1310, 1999.
`
`86. Burris HA: Docetaxel (Taxotere) in HER-2 positive patients and in combination with trastuzumab
`(Herceptin). Semin Oncol 27(2 Suppl 3): 19-23. Review, 2000.
`
`87. Hainsworth JD, Burris HA, Litchy S, Erland JB, Hon JK, Briere JE, Greco FA: Gemcitabine and
`vinorelbine in the second-line treatment of non-small cell lung cancer: A Minnie Pearl Cancer
`Research Network phase II trial. Cancer 88:1353-1358, 2000.
`
`88. Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA:
`Paclitaxel, carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer: A
`phase II trial of the Minnie Pearl Cancer Research Network. Cancer Journal Sci Am 6:151-156, 2000.
`
`89. Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC JR, Bearden JD, Richards P, Greco FA:
`Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s
`lymphoma. Blood 95:3052-3056, 2000.
`
`90. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, Greco FA: Weekly docetaxel in
`the treatment of elderly patients with advanced non-small cell lung cancer: A Minnie Pearl Cancer
`Research Network phase II trial. Cancer 89:328-333, 2000.
`
`91. Greco FA, Burris HA, Erland JB, Cray JR, Kalman LA, Schreeder MT, Hainsworth JD: Carcinoma of
`unknown primary site; Long-term follow-up after treatment with paclitaxel, carboplatin, and
`etoposide. Cancer 89:2655-2660, 2000.
`
`92. Greco FA, Erland JB, Morrissey LH, Burris HA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth
`JD: Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin.
`Ann Oncol 11:211-215, 2000.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NOVARTIS EXHIBIT 2096
`Par v Novartis, IPR 2016-00084
`Page 11 of 80
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`93. Hainsworth JD, Burris HA, Greco FA: Weekly docetaxel in the treatment of elderly or poor
`performance status patients with advanced non-small cell lung cancer. Cancer Conf Highlights 4:2-4,
`2000.
`
`94. Meluch AA, Burris HA, Greco FA, Hainsworth JD: Gemcitabine and paclitaxel combination therapy in
`transitional cell carcinoma of the urothelium. Eur J Cancer 36:S30-S33, 2000.
`
`95. Greco FA, Burris HA, Hainsworth JD: Gemcitabine, paclitaxel, and carboplatin for advanced non-small
`cell lung cancer. Oncology 14(suppl 4):31-34, 2000.
`
`96. Burris HA 3rd, Hainsworth JD, Erland JB, Morrissey LH, Kalman LA, Hon JK, Scullin DC Jr, Smith SW,
`Greco FA: Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin
`in the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27 (1 suppl 2):9-
`13, 2000.
`
`97. Schilsky RL, Bukowski R, Burris HA 3rd, Hochster H, O’Rourke M, Wall JG, Mani S, Bonny T, Levin J,
`Hohneker J: A multicenter phase II study of a five-day regimen of oral 5-fluoruoracil plus eniluracil
`with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol 11(4): 415 – 420,
`2000.
`
`98. Burris HA 3rd: Docetaxel (Taxotere) in the treatment of cancer. Semin Oncol 27 (2 Suppl 3): 1 – 2.
`Review, 2000.
`
`99. Friedman CJ, Burris HA 3rd, Yocom K, Blackburn LM, Gruben D: Oral granisetron for the prevention of
`acute late onset nausea and vomiting in patients treated with moderately emetogenci chemotherapy.
`Oncologist 5(2): 136 – 143, 2000.
`
`100. Hainsworth JD, Burris HA, Calvert SW, Willcutt NT, Scullin DC Jr, Bramham J, Greco FA: Gemcitabine in
`the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the
`Minnie Pearl Cancer Research Network. Cancer Investigation 19:335-339, 2001.
`
`101. Hainsworth JD, Burris HA, Meluch AA, Baker MN, Morrissey LH, Greco FA: Paclitaxel, carboplatin and
`long-term continuous infusion 5-flourouracil in the treatment of advanced squamous carcinoma:
`results of a phase II trial. Cancer 92:642-649, 2001.
`
`102. Greco FA, Gray J, Burris HA, Erland JB, Morrissey LH, Hainsworth

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket